Myth Check: No, a Laser Will Not Cure Your Melasma

Walk into almost any aesthetic practice in the 90210 corridor and you will find a laser being marketed as a melasma solution. The pitch usually involves a low-fluence Q-switched or picosecond device, a package of six to ten sessions, and before-and-after photos taken weeks apart. The claim worth examining: that laser energy can clear melasma and keep it clear. The short answer from pigment researchers and the dermatologists who treat this condition daily is no. Lasers can lighten melasma temporarily. They do not cure it, and used aggressively, they can make it permanently worse.

Why melasma is not just extra pigment. Melasma is a chronic disorder of melanocyte behavior, not a simple deposit of melanin sitting in the skin waiting to be shattered. Affected melanocytes are hyperactive but not increased in number in most studies. The surrounding tissue matters just as much: melasma skin shows increased vascularity, more mast cells, solar elastosis in the dermis, and a compromised basement membrane that allows pigment to drop into the dermis where it becomes very hard to reach. Hormones, ultraviolet light, visible light, and even heat all signal these melanocytes to produce more pigment. That is the core problem with framing any single procedure as a cure. The trigger system stays intact after treatment. You can empty the pigment, but the factory is still running.

What lasers actually do to melasma. Low-fluence 1064 nm Q-switched Nd:YAG treatment, often marketed as laser toning, works by subcellular selective photothermolysis. It fragments melanosomes inside melanocytes and keratinocytes without destroying the cells outright. Picosecond devices do something similar with shorter pulses and more photoacoustic effect. In controlled studies, both produce measurable lightening over a series of sessions. The catch appears in the follow-up data: recurrence rates after stopping treatment are high, frequently within three to six months, and a meaningful minority of patients develop complications. The two most cited are rebound hyperpigmentation, where the melasma returns darker than baseline, and punctate leukoderma, a confetti-like permanent loss of pigment caused by cumulative melanocyte destruction after many repeated sessions. Leukoderma is not reversible. That risk grows with exactly the kind of long treatment packages that clinics sell.

Why heat is the enemy. Melanocytes respond to thermal injury by upregulating pigment production, partly through inflammatory mediators and paracrine signaling from surrounding keratinocytes and fibroblasts. This is why more aggressive devices, including fractional ablative lasers and intense pulsed light at higher settings, have a poor track record in melasma despite working well for sun spots. A solar lentigo is a stable lesion you can destroy. Melasma is a reactive process you can provoke. Skin of color, common among melasma patients, carries additional risk because larger, more numerous melanosomes absorb more energy and inflame more readily.

What actually holds melasma back. The evidence hierarchy is fairly consistent. First, photoprotection, and specifically tinted mineral sunscreen containing iron oxides, because visible light drives melasma and ordinary chemical filters do not block it. Second, topical therapy: triple combination creams pairing hydroquinone, a retinoid, and a mild corticosteroid remain the best studied, with cysteamine, azelaic acid, and tranexamic acid serving as alternatives for maintenance or hydroquinone-sensitive patients. Third, oral tranexamic acid for appropriate candidates under physician supervision, which works by dampening the plasmin pathway that links UV exposure to melanocyte stimulation and by reducing the vascular component. Fourth, gentle chemical peels such as low-strength glycolic acid as adjuncts. Energy devices sit at the bottom of that list, reserved for stubborn cases and always layered on top of topicals and strict sun behavior, never used alone.

Where lasers reasonably fit. There is a defensible role for low-fluence laser toning or picosecond treatment in refractory melasma that has already failed optimized topical therapy, ideally with pretreatment and posttreatment topical suppression running continuously. Some clinicians also use pulsed dye or other vascular lasers to target the dilated vessels that feed melasma, based on the observation that vascular endothelial growth factor signaling stimulates melanocytes. These are adjuncts with modest, temporary benefit, and honest practices present them that way.

Questions to ask before booking. How many total sessions is the practice recommending, and what is the plan if pigment worsens? Is a topical regimen and tinted sunscreen part of the protocol, or is the laser being sold as standalone? Has anyone examined your skin with a Wood's lamp or discussed dermal versus epidermal pigment, which changes the prognosis? A practice that answers these clearly is treating melasma. A practice that promises clearance in a package of sessions is selling a subscription to a condition that, by its biology, does not stay cleared. Melasma is managed, not cured, and the most effective tools are the least glamorous ones: sunscreen, topicals, patience, and realistic expectations.

Related reading: Melasma in Beverly Hills: Why the Wrong Laser Makes It Worse, and What Actually Clears It.